Cannabis: research and patient questions (Page 4)

Clinicians should be cautious when prescribing CBD-dominant cannabis products, as they may produce stronger adverse effects than expected. Understanding cannabinoid interactions is crucial for safe therapeutic use.

Sublingual THC:CBD oil extracts administered at modest, individually titrated daily doses (around 20 mg each) provided statistically significant, modest long-term improvements in chronic pain and associated disease burden (sleep, anxiety, and quality of life) with a reasonable safety profile. However, nearly 40% of patients dropped out by 6 months, and clinician monitoring for CNS and GI side effects remains essential.

Combining a brief motivational interviewing session with 4 weeks of tailored health coaching via a familiar social media platform (Snapchat) is a highly acceptable, engaging approach for reaching cannabis-using emerging adults in emergency care settings. While pilot results show promising improvements in readiness to change, larger definitive trials are needed to confirm long-term behavioral efficacy on consumption.

Consider recommending CBD-dominant cannabis for patients with anxiety symptoms, as it may provide greater relief compared to THC-dominant options.

Clinicians should be aware of the potential driving impairments associated with cannabis use and advise patients accordingly, especially in states where cannabis is legalized.

Cannabis-induced acute pancreatitis should be considered in young patients presenting with acute abdominal pain and elevated pancreatic enzymes in the absence of gallstones or heavy alcohol use. Cessation of cannabis along with conservative supportive care yields favorable recovery without mortality.

Integrative physicians should consider cannabis as a potential treatment for sleep disorders, while paying close attention to dosing to maximize benefits and minimize risks.

While purified CBD is generally well-tolerated in clinical trials, the widespread availability of unregulated CBD-infused foods presents safety risks due to unpredictable dosing, lack of extract standardization, and pronounced increases in bioavailability when consumed with dietary fats. Integrative clinicians should counsel patients on the variability and lack of federal safety oversight in commercial CBD food products, keeping potential drug-drug interactions and elevated liver enzyme risks in mind.

While cannabis use does not show a significant increase in adverse cardiovascular events, clinicians should remain cautious and consider individual patient factors when discussing cannabis use.

Clinicians should consider the varying levels of evidence regarding the efficacy and safety of cannabis and cannabinoids when making treatment decisions. Systematic reviews can provide valuable insights into the credibility of these associations.